Monitorización durante el tratamiento de la pubertad precoz: Guía de práctica clínica para el diagnóstico y el tratamiento de la pubertad precoz

The Mexican Society of Pediatric Endocrinology developed a clinical practice guide for the diagnosis and treatment of precocious puberty. This document presents recommendations related to the monitorization of the treatment and follow-up of patients with central precocious puberty. The detailed description of the methodology for the development of this guide and the grading system, as well as the synthesis of the evidence on which it is based, can be consulted in this same supplement.

[1]  C. Barrón-Uribe,et al.  Puberty blockade: Clinical guideline for the diagnosis and treatment of precocious puberty. , 2020, Boletin medico del Hospital Infantil de Mexico.

[2]  P. Medina-Bravo,et al.  Metodología para la elaboración de la Guía de práctica clínica para el diagnóstico y el tratamiento de la pubertad precoz , 2020 .

[3]  A. Bereket.  A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty , 2017, Journal of clinical research in pediatric endocrinology.

[4]  M. Papagianni,et al.  Anastrozole plus leuprorelin in early maturing girls with compromised growth: the “GAIL” study , 2015, Journal of Endocrinological Investigation.

[5]  M. Kumar,et al.  Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective , 2015, Indian journal of endocrinology and metabolism.

[6]  S. Shalitin,et al.  Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. , 2015, The Journal of clinical endocrinology and metabolism.

[7]  B. Hosmane,et al.  Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty , 2014, Clinical Drug Investigation.

[8]  M. Phillip,et al.  Treated and untreated women with idiopathic precocious puberty: long‐term follow‐up and reproductive outcome between the third and fifth decades , 2014, Clinical endocrinology.

[9]  F. D. de Paula,et al.  Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist , 2012, Clinics.

[10]  P. A. Lee,et al.  Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  E. Neely,et al.  A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. , 2011, The Journal of pediatrics.

[12]  Peter A. Lee,et al.  Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study , 2011, International journal of pediatric endocrinology.

[13]  A. Alikaşifoğlu,et al.  GnRH Stimulation Test in Precocious Puberty: Single Sample is Adequate for Diagnosis and Dose Adjustment , 2011, Journal of clinical research in pediatric endocrinology.

[14]  V. Mericq,et al.  Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results , 2009, Clinical endocrinology.

[15]  P. Erba,et al.  Body Mass Index and Body Composition in Adolescents Treated with Gonadotropin-Releasing Hormone Analogue Triptorelin Depot for Central Precocious Puberty: Data at Near Final Height , 2009, Neuroendocrinology.

[16]  M. Segni,et al.  Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  H. Delemarre-van de Waal,et al.  Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  S. Wacharasindhu,et al.  Bone mineral density and body composition in Thai Precocious Puberty girls treated with GnRH agonist. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[19]  F. Waldhauser,et al.  Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function , 2006, Molecular and Cellular Endocrinology.

[20]  Darrell M. Wilson,et al.  Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  D. Mul,et al.  Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone , 2005, Clinical endocrinology.

[22]  A. Latronico,et al.  A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  M. Segni,et al.  Effects of Combined Gonadotropin-Releasing Hormone Agonist and Growth Hormone Therapy on Adult Height in Precocious Puberty: A Further Contribution , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[24]  M. Phillip,et al.  Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  D. Mul,et al.  Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty , 2001, Clinical endocrinology.

[26]  A. Pasquino,et al.  When to Stop GnRH Analog Therapy: The Experience of the Italian Study Group for Physiopathology of Puberty , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[27]  S. Heger,et al.  Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  D. Mul,et al.  Auxological and Biochemical Evaluation of Pubertal Suppression with the GnRH Agonist Leuprolide Acetate in Early and Precocious Puberty , 1999, Hormone Research in Paediatrics.

[29]  A. Balsamo,et al.  Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5–8.5 years , 1999, Archives of disease in childhood.

[30]  A. Pasquino,et al.  Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. , 1999, European journal of endocrinology.

[31]  M. Segni,et al.  Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  Z. Laron,et al.  Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. , 1997, Hormone research.

[33]  R. Odink,et al.  Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. , 1996, Archives of disease in childhood.